Performance of native and gadoxetate-enhanced liver and spleen T₁ mapping for noninvasive diagnosis of clinically significant portal hypertension: preliminary results

Purpose: In this preliminary study, our aim was to assess the utility of quantitative native-T₁ (T₁-pre), iron-corrected T₁ (cT₁) of the liver/spleen and T₁ mapping of the liver obtained during hepatobiliary phase (T₁-HBP) post-gadoxetate disodium, compared to spleen size/volume and APRI (aspartate aminotransferase-to-platelet ratio index) for noninvasive diagnosis of clinically significant portal hypertension [CSPH, defined as hepatic venous pressure gradient (HVPG) ≥ 10 mm Hg]. Methods: Forty-nine patients (M/F: 27/22, mean age 53y) with chronic liver disease, HVPG measurement and MRI were included. Breath-held T₁ and cT₁ measurements were obtained using an inversion recovery Look-Locker sequence and a T2* corrected modified Look-Locker sequence, respectively. Liver T₁-pre (n = 49), spleen T₁ (obtained pre-contrast, n = 47), liver and spleen cT₁ (both obtained pre-contrast, n = 30), liver T₁-HBP (obtained 20 min post gadoxetate disodium injection, n = 36) and liver T₁ uptake (ΔT₁, n = 36) were measured. Spleen size/volume and APRI were also obtained. Spearman correlation coefficients were used to assess the correlation between each of liver/spleen T₁/cT₁ parameters, spleen size/volume and APRI with HVPG. ROC analysis was performed to determine the performance of measured parameters for diagnosis of CSPH. Results: There were 12/49 (24%) patients with CSPH. Liver T₁-pre (r = 0.287, p = 0.045), liver T₁-HBP (r = 0.543, p = 0.001), liver ΔT₁ (r = − 0.437, p = 0.008), spleen T₁ (r = 0.311, p = 0.033) and APRI (r = 0.394, p = 0.005) were all significantly correlated with HVPG, while liver cT₁, spleen cT₁ and spleen size/volume were not. The highest AUCs for the diagnosis of CSPH were achieved with liver T₁-HBP, liver ΔT₁ and spleen T₁: 0.881 (95%CI 0.76–1.0, p = 0.001), 0.852 (0.72–0.98, p = 0.002) and 0.781 (0.60–0.95, p = 0.004), respectively. Conclusion: Our preliminary results demonstrate the potential of liver T₁ mapping obtained during HBP post gadoxetate disodium for the diagnosis of CSPH. These results require further validation. Graphical abstract: [Figure not available: see fulltext.]